M. I. Kulikova

M. I. Kulikova

Auto-generated profile, based on publicly available information

M. I. Kulikova

Russian Medical Academy for Continuing Professional Education

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Drug Metabolism and Drug Interactions
Verified
Journal Article
Closed access
DSDmitry Sychev
Dmitry Sychev
KMKarin Mirzaev
Karin Mirzaev
MCMarina S. Cherniaeva
Marina S. Cherniaeva
MKMaria Kulikova
Maria Kulikova
PBPavel Olegovich Bochkov
Pavel Olegovich Bochkov
EREric Rytkin
Eric Rytkin
Objectives: For revealing the peculiarities of the drug–drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil – inhibitor CYP3A4 and P-gp and amlodipine – substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients. Methods: All patients were divided into groups depending on the therapy taken: the 1st – rivaroxaban + amlodipine (n=51), the 2nd – rivaroxaban + verapamil (n=30), the control group – rivaroxaban without CCBs (n=47). A trough steady-state plasma concentration (C min,ss) of rivaroxaban, prothrombin time (PT) in the blood plasma and the event of clinically relevant non-major (CRNM) bleeding were assessed for each patient. Results: Patient in group 2 had higher C min,ss of rivaroxaban, PT and CRNM than subjects in the control group (Me 73.8 [50.6–108.8] ng/mL vs. 40.5 [25.6–74.3] ng/mL; Me 14.8 [13.4–17.3] s vs. 13.8 [12.6–14.4] s; 34% vs. 13%, respectively, p0.05 for all). Conclusions: In patients ≥80 years with NAF, the use of rivaroxaban in combination with verapamil may not be safe and can lead to CRNM bleeding.

2 September 2019 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
OOO. D. Ostroumova
O. D. Ostroumova
MKM. I. Kulikova
M. I. Kulikova
DSDmitry Sychev
Dmitry Sychev
OGO. V. Golovina
O. V. Golovina
MCM. S. Chernyaeva
M. S. Chernyaeva
Влияние лекарственных препаратов с антихолинергической активностью на когнитивные функции пациентов 80 лет и старше с эссенциальной артериальной гипертензией

4 September 2020 in Drug Metabolism and Personalized Therapy
Verified
Journal Article
Closed access
DSDmitry Sychev
Dmitry Sychev
KMKarin Mirzaev
Karin Mirzaev
MCMarina S. Cherniaeva
Marina S. Cherniaeva
MKMaria Kulikova
Maria Kulikova
PBPavel Olegovich Bochkov
Pavel Olegovich Bochkov
EREric Rytkin
Eric Rytkin
Objectives: For revealing the peculiarities of the drug–drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil – inhibitor CYP3A4 and P-gp and amlodipine – substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients. Methods: All patients were divided into groups depending on the therapy taken: the 1st – rivaroxaban + amlodipine (n=51), the 2nd – rivaroxaban + verapamil (n=30), the control group – rivaroxaban without CCBs (n=47). A trough steady-state plasma concentration (C min,ss) of rivaroxaban, prothrombin time (PT) in the blood plasma and the event of clinically relevant non-major (CRNM) bleeding were assessed for each patient. Results: Patient in group 2 had higher C min,ss of rivaroxaban, PT and CRNM than subjects in the control group (Me 73.8 [50.6–108.8] ng/mL vs. 40.5 [25.6–74.3] ng/mL; Me 14.8 [13.4–17.3] s vs. 13.8 [12.6–14.4] s; 34% vs. 13%, respectively, p0.05 for all). Conclusions: In patients ≥80 years with NAF, the use of rivaroxaban in combination with verapamil may not be safe and can lead to CRNM bleeding.

15 April 2022 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
OOO. D. Ostroumova
O. D. Ostroumova
DSDmitry Sychev
Dmitry Sychev
AKA. I. Kochetkov
A. I. Kochetkov
TOT. M. Ostroumova
T. M. Ostroumova
MKM. I. Kulikova
M. I. Kulikova
VDV. A. De
V. A. De
Some drugs can lead to the development of drug-induced arterial hypertension. The aim of the work is to systematize and analyze the data about drugs that can cause the development of drug-induced hypertension, as well as on epidemiology, pathophysiological mechanisms, risk factors, clinical picture, diagnosis and differential diagnosis, treatment and prevention of drug-induced hypertension. As a result of data analysis, it was revealed that drugs: glucocorticosteroids, antineoplastic drugs, immunosuppressants, nonsteroidal anti-inflammatory drugs, antidepressants and some others are associated with the development of hypertension. The mechanisms of development of drug-induced arterial hypertension are not fully established and require further study. Drug-induced arterial hypertension is still one of the most common and often unrecognized adverse reactions. The clinical manifestations of drug-induced hypertension are not specific. The symptoms are associated with target organ damage or complications of hypertension and may include a headache, nausea, dizziness, blurred vision, anxiety, shortness of breath, etc. patients with previously well-controlled hypertension or cases of uncontrolled hypertension. Therefore, it is always necessary to pay attention to the patient’s history, pharmacological anamnesis, rapid increases in blood pressure in patients with previously well-controlled hypertension, or cases of uncontrolled hypertension.

7 September 2022 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
OOO. D. Ostroumova
O. D. Ostroumova
DSDmitry Sychev
Dmitry Sychev
AKA. I. Kochetkov
A. I. Kochetkov
TOT. M. Ostroumova
T. M. Ostroumova
MKM. I. Kulikova
M. I. Kulikova
VDV. A. De
V. A. De
Arterial hypertension is one of the most common comorbidities in patients with cancer. Moreover, the treatment with anticancer agents can lead to the development of drug-induced arterial hypertension.   The aim of this work is to systematize and analyze data about anticancer agents, the use of which can cause the development of drug-induced hypertension, about epidemiology, pathophysiological mechanisms, risk factors, clinical signs, diagnosis and differential diagnosis, treatment and prevention of hypertension associated with the use of anticancer drugs. It was found that anti-cancer drugs often contribute to the development of drug-induced hypertension. The mechanisms that determine the development of hypertension are diverse and may include the development of endothelial dysfunction, an increased arterial stiffness, capillary rarefaction, fluid and electrolyte imbalance, and genetic factors. It is important to remember about drugs that can cause drug-induced hypertension to reduce the risk of developing adverse reactions, and prevent cardiovascular disease. Treatment of drug-induced hypertension, caused by anticancer drugs, often requires immediate discontinuation of drugs, due to adverse reactions that are often life-threatening. In some situations, it is possible to reduce the dose of the drugs and / or prescribe antihypertensive drugs. Arterial hypertension is an important risk factor in the development of cardiovascular events, including stroke, coronary heart disease, heart failure.